Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Beneski reported a small open-market sale of 4,835 shares of Common Stock at a weighted average price of $2.47 per share. The shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plan and were required by a “sell to cover” election, meaning the transaction was not a discretionary trade. After this sale, Beneski directly holds 198,205 shares of Allogene common stock.
Allogene Therapeutics President and CEO David D. Chang reported an open‑market sale of 47,763 shares of common stock at $2.47 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandatory “sell to cover” feature of the company’s equity incentive plan, so this was not a discretionary trade. After the transaction, Chang directly holds 5,150,599 common shares, and additional shares are held indirectly through the RTC 2019 Trust, JEC 2019 Trust, and the Chang 2006 Family Trust.
Allogene Therapeutics filed a Form 144 reporting a proposed sale of 4,835 shares of Common Stock listed on NASDAQ. The filing shows a related vesting of a restricted stock unit award on 03/13/2026 granted under the issuer's equity compensation plan. The Form 144 entry is dated 03/16/2026.
Allogene Therapeutics reported a Form 144 notice for 47,763 shares of Common Stock related to the vesting of restricted stock units on 03/13/2026. The filing lists these shares as granted under the issuer's equity compensation plan and shows the transaction date as 03/13/2026.
Allogene Therapeutics, Inc. files its annual report as a clinical-stage company focused on off‑the‑shelf, allogeneic CAR T therapies for cancer and autoimmune disease. Its approach uses gene‑edited donor T cells and a proprietary Dagger® technology to improve persistence and limit rejection.
The company’s strategy centers on three core programs: cema‑cel for large B‑cell lymphoma in the pivotal Phase 2 ALPHA3 first‑line consolidation trial, ALLO‑316 for renal cell carcinoma with RMAT designation, and ALLO‑329 for systemic autoimmune diseases with multiple Fast Track designations. Interim ALPHA3 MRD data are planned for April 2026 and initial ALLO‑329 proof‑of‑concept data for June 2026. Allogene highlights substantial accumulated and expected future losses, heavy dependence on a few lead assets and partners, manufacturing and regulatory complexity, and significant competition from autologous CAR T and other novel therapies.
Allogene Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its allogeneic CAR T pipeline. The pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma is underway, with an interim futility analysis focused on MRD clearance and early safety planned for April 2026.
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026. The company ended Q4 2025 with $258.3 million in cash, cash equivalents and investments, guiding that its cash runway extends into the first quarter of 2028. Full-year 2025 net loss was $190.9 million, or $0.87 per share.
Allogene Therapeutics, Inc. senior vice president and chief technical officer Benjamin Machinas Beneski reported a mandatory sale of common stock to cover taxes on vested restricted stock units. He sold 7,132 shares in a sell-to-cover transaction at a weighted average price of $2.60 per share, with individual sale prices ranging from $2.60 to $2.67. After this tax-related sale, he directly owned 203,040 shares of Allogene common stock. The filing notes this transaction was required under the company’s equity incentive plan and did not represent a discretionary trade by the executive.
Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on 02/28/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the market.
Allogene Therapeutics, Inc. shareholder Arie Belldegrun reports beneficial ownership of 13,248,170 shares of common stock, equal to 5.8% of the company as of December 31, 2025. This total includes 3,885,280 shares issuable within 60 days upon exercise of stock options.
The filing aggregates shares held directly and through Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P. Ownership percentages are calculated using 224,730,144 Allogene shares outstanding as of November 4, 2025.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.